PatientsVille.com Logo

MEMORY IMPAIRMENT and Ranitidine

PatientsVille

MEMORY IMPAIRMENT Symptoms and Causes

Every day, you have different experiences and you learn new things. Your brain cannot store all of that information, so it has to decide what is worth remembering. Memory is the process of storing and then remembering this information. There are different types of memory. Short-term memory stores information for a few seconds or minutes. Long-term memory stores it for a longer period of time.

Memory doesn't always work perfectly. As you grow older, it may take longer to remember things.

It's normal to forget things once in awhile. We've all forgotten a name, where we put our keys, or if we locked the front door. If you are a senior who forget things more often than others your age, you may have mild cognitive impairment. Forgetting how to use your phone or find your way home may be signs of a more serious problem, such as

  • Alzheimer's disease
  • Other types of dementia
  • Stroke
  • Depression
  • Head injuries
  • Blood clots or tumors in the brain
  • Kidney, liver, or thyroid problems
  • Reactions to certain medicines

If you're worried about your forgetfulness, see your health care provider.

NIH: National Institute on Aging

Check out the latest treatments for MEMORY IMPAIRMENT

MEMORY IMPAIRMENT treatment research studies

Ranitidine clinical trials, surveys and public health registries


Find Drug Side Effect reports



Ranitidine Side Effects

Dyspnoea (125)
Anaphylactic Reaction (77)
Hypotension (71)
Diarrhoea (67)
Nausea (65)
Vomiting (62)
Urticaria (59)
Abdominal Pain (46)
Dizziness (43)
Malaise (43)
Cardiac Arrest (40)
Pain (39)
Loss Of Consciousness (37)
Fatigue (36)
Angioedema (35)
Confusional State (34)
Renal Failure Acute (33)
Pruritus (32)
Headache (32)
Chest Pain (31)
Abdominal Pain Upper (29)
Overdose (27)
Bradycardia (27)
Rash (27)
Pyrexia (25)
Hypersensitivity (24)
Dyspepsia (23)
Circulatory Collapse (23)
Chest Discomfort (22)
Erythema (21)
Thrombocytopenia (21)
Gastrooesophageal Reflux Disease (21)
Product Quality Issue (21)
Weight Decreased (20)
Burning Sensation (20)
Alanine Aminotransferase Increased (20)
Paraesthesia (20)
Cholelithiasis (20)
Dysgeusia (19)
Neutropenia (19)
Cough (19)
Flushing (19)
Hypertension (19)
Tubulointerstitial Nephritis (18)
Condition Aggravated (17)
Feeling Abnormal (17)
Depression (17)
Vision Blurred (17)
Agitation (16)
Heart Rate Increased (16)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Emotional Anxciety then chest pain, jaw pain on left side and headaches, I am not taking it no more. there has to be something else less tramatising to my system. It was bad enugh that i was at work when the emotional anxiety hit. not cool at all.

<strong>gracia por la informacion</strong>

*DONT_KNOW* guess that's an honest answer

Has there been any evidence linking ranitidine to lower back or hip problems?

Is Histac 150 a pain reliever for slip disc backache?

Will Marinol further damage, an already diseased liver

As you know, I asked I thought, for the impossible. To refresh you all memory I was very much in love with my best friend (we are both women) well she decided to leave her fianc nine weeks after I ordered your Powerful Love Spell. I am not sure i

since i started novothyral my pulse jumped, and tired,memory problems,my body feels week,unable to do anythyng physical, all in all my life going nowhere since two months ago when i started taking this pill thanks very much a

Have taken hydrea for a year because my spleen had increased in size. I have noticed increased loss of memory and some confusion for the past couple of months. I take 500 mg every other day and 1000 mg every other day.

I am having cramps, muscle pain, memory loss, I have been on Revlmid for about 1 year. Does anybody else my age have this disease, I am only 46 yr woman.

Extreme fatigue, sleeplessness, short term memory and speech difficulties, Edema, weight gain, stumbling, shortness of breath, numbness in both legs, and completely kills ability to achieve orgasm.

<span style='color: #808080;'><b>What do You think about Vision impairment and blindness?</b>

Anon- I would say the weed would cause the MOST memory loss used over time also depending on how strong it is ie, (haze, kush....dro...regs from 60's with seeds) THE STONGER it is the faster the brain cells go! As far as the valium/dia

<strong>Found Celepram effective at the end of the 3rd week. Effectiveness lasted for around 14 days. Following period i experienced continualled short term memory loss, hallucinations of seeing stars, skin irritated rash, shortness of breath &

45 Male on Enbrel 4 + years , My condition is all but gone and I really use no other meds now. Expect a dry cough , Poor night vision ,Memory loss ,and in some cases (345) amniesia. IHAVE noticed a difficulty in learning new&am

8 day ago I had an endoscopy where they used Versed. Since then I have had a horrible time with short term memory. I have had episodes of feeling agressive, angry and verbally hostile and seemed to be 'out of control'.&a

MEMORY IMPAIRMENT Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Comparison of Pantoprazole and Ranitidine in Dyspepsia
Condition: Dyspepsia
Interventions: Drug: Pantoprazole;   Drug: Ranitidine
Outcome Measures: Visual analogue scale score;   Need for additional drug
2 Recruiting TPI 287 in Breast Cancer Metastatic to the Brain
Condition: Breast Cancer
Interventions: Drug: TPI 287;   Drug: Dexamethasone;   Drug: Benadryl;   Drug: Ranitidine
Outcome Measure: Overall Response Rate
3 Recruiting Treatment of Orthostatic Hypotension in Autonomic Failure
Conditions: Autonomic Failure;   Orthostatic Hypotension
Interventions: Drug: Atomoxetine;   Drug: Acarbose;   Drug: Pyridostigmine Bromide;   Drug: Yohimbine;   Drug: Midodrine HCl;   Drug: placebo;   Drug: Modafinil;   Drug: Octreotide;   Other: water intake;   Drug: Diphenhydramine Hydrochloride;   Drug: Ranitidine HCL;   Drug: Tranylcypromine;   Drug: Ergotamine/ Caffeine;   Drug: Celecoxib;   Drug: Pseudoephedrine;   Drug: Methylphenidate;   Drug: Indomethacin;   Drug: Ibuprofen;   Drug: Oxymetazoline 0.05% nasal solution;   Dietary Supplement: Bovril;   Drug: Acetazolamide;   Drug: Rivastigmine tartrate;   Drug: Carbidopa/levodopa;   Device: Inflatable abdominal binder;   Device: inflatable abdominal binder (sham)
Outcome Measures: Increase in seated systolic blood pressure 1-hr post drug compared to baseline.;   Increase in standing time 1-hr post drug compared to baseline
4 Not yet recruiting The Study of Eustachian Tube Dysfunction and Laryngopharyngeal Reflux
Conditions: Eustachian Tube Dysfunction;   Laryngopharyngeal Reflux
Interventions: Drug: Omeprazole;   Drug: Ranitidine;   Drug: Pantoprazole;   Procedure: 24-Hour Diagnostic pH-Probe Test;   Procedure: Laryngoscopy
Outcome Measure: Evidence of laryngopharyngeal reflux in patients complaining of ear fullness/pressure/pain
5 Recruiting Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents
Conditions: Pharmacokinetics;   Voriconazole
Intervention: Drug: Midazolam/Ranitidine/Esomeprazole
Outcome Measures: Voriconazole steady-state pharmacokinetics;   Voriconazole drug metabolizing enzyme activity
6 Recruiting Clinical Trial Corticoids For Empyema And Pleural Effusion In Children
Conditions: Parapneumonic Pleural Effusion;   Empyema
Interventions: Drug: Dexamethasone;   Drug: Placebo
Outcome Measures: time to resolution;   number of children with complications.;   Number of children with complications attributable to corticoids
7 Unknown  Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects
Condition: Poisoning
Interventions: Drug: Chlorphenamine and Ranitidine;   Drug: Paracetamol
Outcome Measures: Attenuation of NAC induced vasodilatation by histamine antagonists (H1 and H2 antagonists) and/or paracetamol;   Inhibition of the inflammatory cascade contributes to a paracetamol mediated protective role against NAC adverse reactions.
8 Unknown  Antibiotic Resistant Helicobacter Pylori in Rajavithi Hospital
Condition: Dyspepsia
Intervention: Procedure: gastroscopic examination
Outcome Measures: Incidence of H. pylori Clarithromycin resistance gene;   Characteristic of H. pylori clarithromycin resistant gene mutation
9 Unknown  Efficacy of Acetilcysteine in 'Rescue' Therapy for Helicobacter Pylori Infection. Pilot Study
Condition: Helicobacter Pylori Infection
Interventions: Drug: Group A: NCA 600 mg+antibiotics;   Drug: Group B: antibiotic treatment (control)
Outcome Measure: To evaluate the usefulness of NAC as pre-treatment attempt associated with a culture-guided antibiotic therapy as rescue therapy after multi-attempts antibiotic failure
10 Recruiting Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme
Condition: Glioblastoma Multiforme (GBM) WHO Grade IV
Intervention: Drug: Cabazitaxel
Outcome Measures: Response including SD, PR or CR determined by MRI (modified RANO criteria);   Overall and progression-free survival;   Safety and tolerability;   Pharmacokinetics data concerning drug interactions (i.e. CYP3A induction);   Quality of life and neurocognitive functioning
11 Recruiting Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Intervention: Drug: carboplatin
Outcome Measures: To determine if patients have lower rates of hypersensitivity reactions compared to those treated with standard infusion carboplatin.;   Determine the rate of successful planned treatment completion of carboplatin in each group;   Perform a cost-identification analysis of extended infusion carboplatin to estimate the cost per hypersensitivity reaction prevented.;   Perform exploratory analyses to correlate hypersensitivity rate to history of atopy, prior drug allergies, number of lifetime platinum cycles, duration since last platinum, and concomitant chemotherapy agent.
12 Not yet recruiting Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)
Condition: Breast Neoplasms
Interventions: Drug: Vintafolide 2.5 mg;   Drug: Paclitaxel 80 mg/m^2;   Drug: Etarfolatide;   Drug: Folic acid;   Drug: Premedication for Paclitaxel
Outcome Measures: Progression Free Survival (PFS);   Objective Response Rate (Complete Response [CR] + Partial Response [PR]);   Clinical Benefit Rate (CR + PR + Stable Disease [SD] for >=6 months);   Overall Survival (OS)
13 Recruiting MAGIC vs. CROSS Upper GI. ICORG 10-14, V3
Conditions: Adenocarcinoma of the Oesophagus;   Adenocarcinoma of the Oesophago-gastric Junction;   Oesophageal Tumours;   Junctional Tumours;   Oesophageal Cancer
Interventions: Drug: Epirubicin;   Drug: Cisplatin;   Drug: 5 Flourouracil/ Capecitabine;   Radiation: (41.4 Gy/23 fractions);   Drug: Paclitaxel;   Drug: Carboplatin
Outcome Measure: Overall survival
14 Recruiting Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer
Condition: Neoplasms
Interventions: Drug: Paclitaxel;   Drug: Copanlisib (BAY80-6946)
Outcome Measures: Adverse event collection;   Maximum tolerated dose, measured by adverse event profile;   Pharmacokinetics characterized by Cmax of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by Cmax/D of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by tmax of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by AUC(0-tlast) of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by AUC (if possible) of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by AUC/D of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by half-life of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by partial AUC values [eg, AUC(0-25)] of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by clearance of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by volume of distribution of BAY80-6946 (and its metabolite(s), if needed);   Estimation of percent of dose excreted [unchanged or as metabolites, if relevant) renally during 0 - 25 h after start of BAY80-6946 infusion (AE,ur(0-25)] (for Cohort 4 only);   Pharmacokinetics characterized by Cmax of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by tmax of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by AUC(0-t) of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by AUC of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by half-life of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by clearance of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by volume of distribution (If possible and needed) of Paclitaxel and 6-OH paclitaxel;   Effect of BAY80-6946 on paclitaxel PK will be assessed by comparing Cmax of Cycle 1 Day 1 and Cycle 1 Day 15;   Effect of BAY80-6946 on paclitaxel PK will be assessed by comparing AUC(0-tlast) of Cycle 1 Day 1 and Cycle 1 Day 15;   Number of patients with mutational status;   Tumor Response as measured by RECIST 1.1 criteria
15 Recruiting Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
Conditions: Non-small Cell Lung Cancer;   Advanced Non-small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Hydroxychloroquine;   Drug: Bevacizumab
Outcome Measures: Antitumor activity, as measured by tumor response rate of hydroxychloroquine, paclitaxel, carboplatin, and bevacizumab (for eligible patients) in patients with advanced or recurrent NSCLC cancer;   Time to progression;   Survival;   Overall survival;   Toxicity of hydroxychloroquine, paclitaxel, carboplatin, and bevacizumab (for eligible patients) in patients with advanced or recurrent NSCLC cancer
16 Unknown  Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors
Conditions: Brain and Central Nervous System Tumors;   Extragonadal Germ Cell Tumor;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions: Biological: filgrastim;   Biological: lenograstim;   Biological: pegfilgrastim;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: ifosfamide;   Drug: paclitaxel
Outcome Measures: Maximum tolerated dose of gemcitabine hydrochloride when administered with TIP chemotherapy comprising paclitaxel, ifosfamide, and cisplatin with growth factor support (phase I);   Response rates (phase I);   Failure-free survival (phase I);   Utility of positron emission tomography scanning after Gem-TIP chemotherapy (phase I);   Degree of dose intensification achieved with Gem-TIP chemotherapy relative to a previous Medical Research Council study with TIP alone (phase II)